MENU

Chrissie Thirlwell

October 10, 2015

Chrissie Thirlwell, BSc, MD, PhD, FRCP

Leave it blank

Biography

Qualifications/Training

Dr Chrissie Thirlwell graduated in Medicine from University College London Medical School, she took an intercalated BSc in Immunology. Her post-graduate adult medical training was with the St. Barthlomews Hospital training rotation, and medical oncology training with Chelsea and Westminster, Charing Cross, Hammersmith and University College London Hospitals.

Her PhD in colorectal cancer genetics was funded by the Medical Research Council and undertaken at the Cancer Research UK London Research Institute. Whilst completing her Medical Oncology training she held a National Institute of Health Research Clinical Lecturer post until her Consultant appointment in 2010.

Since then she has been a Senior Lecturer and Consultant Medical Oncologist at the UCL Cancer Institute and Royal Free Hospital and is a lead Consultant in the multi-disciplinary neuroendocrine tumour and hepatocellular cancer teams. She has a national and international reputation for research in to and the management of neuroendocrine tumours.

Current Roles

Chair of the UK and Ireland Neuroendocrine Tumour Society Research Committee

Scientific advisor to the NET Research Foundation

Co-Chair of the Royal Free Hospital Oncology Trials Facilitation Committee

Grant and abstract reviewer for the American Association of Cancer Research (AACR) and the European Neuroendocrine Tumour society

Undergraduate education lead at UCL Cancer Institute

Research Interests/Publications

Dr Thirlwell leads a research group at the UCL Cancer Institute and has a particular interest in integrated genomic and circulating free DNA analysis in neuroendocrine and other solid tumours. This is to further our understanding of how these tumours develop and identify novel therapeutic targets. She has a number of collaborations within the UK and at Harvard, Bern, Madrid and Uppsala Universities.

To date she has successfully identified sub-groups of NETs which have poorer clinical outcome – which will help to stratify and personalize treatment and also successfully isolated and sequenced DNA from NET cells which is circulating in the bloodstream.

In the last five years she has delivered plenary lectures at the UK, European and North American Neuroendocrine Tumour meetings and received national and international prizes and awards for research undertaken by her team.

She has 39 publications related to cancer genetics, epigenetics and the management of neuroendocrine tumours in peer-reviewed journals such as Nature Genetics, Lancet Oncology, Journal of Clinical Oncology and Clinical Cancer Research.

Profession:

Senior Lecturer and Consultant in Medical Oncology
Royal Free Hospital NET Unit and University College London Cancer Institute